Key points:

• Take advantage of all incentives and tools made available and engage early with national competent authorities, the European Medicines Agency (EMA) and other relevant stakeholders in the network
• Selection of the relevant tool at a given time for a given topic for a given expected outcome can be difficult and a sound regulatory strategy is critical

To read more key points and the session summary, log in as a member or register for free using the links below.